STATEMENT ON JOHNSON & JOHNSON RESTRICTING 340B DISCOUNTS
WASHINGTON, D.C. — Today, Johnson & Johnson, the world's largest drug company, announced it plans to limit 340B discount pricing for safety-net hospitals that partner with community pharmacies. The J&J policy, which will begin on May 2, covers 29 of its best-selling drugs treating conditions ranging from psoriasis to schizophrenia, multiple myeloma, and HIV.
The following statement is attributed to 340B Health President and CEO Maureen Testoni:
“Today’s announcement by Johnson & Johnson, the world’s biggest drug company, to restrict 340B discount pricing for safety-net hospitals flies in the face of the statute written by Congress and the warnings of both the Trump and Biden administrations. By limiting access to mandatory price discounts, J&J will harm the health care safety net and the millions of Americans with low incomes who rely on it for their care.”
“By taking this action, J&J becomes the 16th drug maker to take the law into their own hands. These are some of the world’s largest and most profitable companies, and their actions break their promise to support the safety net in return for billions of annual drug sales to Medicaid and Medicare patients.”
“A bipartisan majority of Congress has called for an end to these violations and a restoration of the 340B program. We will continue to work with the administration and Congress to put an end to these actions before the damage to the safety net becomes extreme.”